艾曲泊帕、重组人血小板生成素联合标准免疫抑制治疗重型再生障碍性贫血16例疗效及安全性分析

Efficacy and safety analysis of eltrombopag and recombinant human thrombopoietin combined with immunosuppressive therapy for severe aplastic anemia

目的评价艾曲泊帕、重组人血小板生成素(Recombinant human thrombopoietin,rhTPO)联合标准免疫抑制治疗(Immunosuppressive therapy,IST)对重型再生障碍性贫血(Severe aplastic anemia,SAA)的疗效及安全性。方法回顾性分析2017年1月1日至2020年6月30日河南省肿瘤医院16例接受IST联合艾曲泊帕、rhTPO治疗的SAA患者,评价其疗效及安全性。结果艾曲泊帕、rhTPO联合标准IST治疗后3个月血液学反应率为81.3%,完全血液学缓解率为37.5%,6个月血液学反应率为87.5%,完全血液学缓解率为50.0%,脱离血小板输注中位时间为35(16~78)d,脱离红细胞输注中位时间为47.5(15~105)d,血小板输注中位量为5.5(3~20)U,红细胞输注中位量为6.5(2~16)U。结论艾曲泊帕联合rhTPO可提高SAA的IST血液学反应率,改善血液学缓解质量,且不良反应轻微。

Objective To evaluate the efficacy and safety of combination therapy of eltrombopag,recombinant human thrombopoietin(rhTPO),and standard immunosuppressive therapy(IST)for severe aplastic anemia(SAA).Methods A total of 16 cases with SAA treated with IST combined with eltrombopag and rhTPO were retrospectively analyzed.Results At 3 months,the total response rate was 81.3%,and the complete hematological response rate was 37.5%.At 6 months,the total response rate was 87.5%,and the complete hematological response rate was 50.0%.The median time of platelet transfusion independence was 35(16-78)days,the median time of red blood cell transfusion independence was 47.5(15-105)days,the median platelet transfusion was 5.5(3-20)U,and the median red blood cell transfusion was 6.5(2-16)U.Conclusion The combination of eltrombopag and rhTPO can improve the hematological response rate of IST for SAA and the quality of hematological remission with minimal toxic effects.